All In Biotech

Drug Trial Radar · NCT06178523

Cost-effective Treatment of Unexplained Infertility

Cost-effective Treatment of Unexplained Infertility: A Prospective Multicenter, Double-blinded, Randomised Controlled Study

Last checked: Nov 19, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

900

Actual

Start

Jan 1, 2024

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Batterjee Medical CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The issue of unexplained infertility that Southam brought up in 1960 is still a problem today. Despite improvements in infertility assessment, many couples still don't know why they are infertile. Even with the use of the most advanced ovulation detectors, fallopian tube patency tests, and semen evaluations, competency cannot identify every potential flaw in the intricate processes leading to conception. Unexplained infertility will be a challenge for both biological and clinical researchers since it results from these gaps in our understanding of fertilization and from our incapacity to use all of the current evidence-based information.

Conditions

  • Unexplained Infertility

Interventions

  • Clomiphene Citrate.Drug

    Clomiphene Citrate (Clomid®) 100 mg for 5 days starting from the second day of the menstrual cycle (Groups A, B, and C).

  • Sildenafil CitrateDrug

    Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle (Group-A).

  • Intrauterine InseminationProcedure

    IUI (Group-B).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pregnancy outcomeTime frame: 7 weeks after positive pregnancy test.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Batterjee Medical College

    Jeddah, Mecca Region, Saudi Arabia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.